Palleon Pharmaceuticals is a clinical-stage biotechnology company at the forefront of discovering and developing novel cancer immunotherapies. They are pioneering the field of glyco-immunology, focusing on the modulation of cell-surface glycans to overcome immunosuppression and unlock the body's anti-tumor immune response. Palleon's proprietary Sialoglycobiology Platform and EAGLE (Enzymatic Antibody Glycan Ligation) Platform enable the creation of first-in-class therapeutics, including enzyme-based candidates and glycan-specific ADCs, aimed at treating a wide range of cancers with significant unmet medical needs.
The headquarters serves as the primary center for Palleon's research and development, clinical operations, strategic partnerships, and corporate administration.
The facility is equipped with state-of-the-art laboratories for drug discovery, biologic development, and translational research, alongside modern office and collaborative workspaces designed to foster scientific innovation.
Palleon fosters a dynamic, science-driven work culture characterized by innovation, collaboration, and a strong commitment to scientific rigor and patient impact. Employees are typically mission-oriented, working towards breakthroughs in cancer therapy.
Its location in the Boston biotech hub provides Palleon with access to a rich talent pool, leading academic institutions, potential collaborators, and a supportive ecosystem for life science companies.
While Palleon Pharmaceuticals is headquartered in the United States, its scientific research, collaborations, and clinical trial activities have a global reach. The company engages with international research institutions, contract research organizations (CROs), and clinical sites to advance its pipeline of glyco-immunology therapies for cancer patients worldwide. Their focus on novel biological pathways has relevance across the international scientific and medical communities.
200 West Street, Suite W310
Waltham
Massachusetts
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Palleon Pharmaceuticals' leadership includes:
Palleon Pharmaceuticals has been backed by several prominent investors over the years, including:
Over the past year, Palleon Pharmaceuticals experienced a significant change in its financial leadership with the departure of its Chief Financial Officer. The company currently does not list a CFO on its executive team page.
Discover the tools Palleon Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Palleon Pharmaceuticals commonly uses an email format that combines the first initial of an employee's first name with their full last name, followed by '@palleonpharma.com'. While other formats might exist within the organization, this is a frequently observed pattern.
[first_initial][last]@palleonpharma.com
Format
jbroderick@palleonpharma.com
Example
85%
Success rate
Business Wire • April 9, 2024
Palleon Pharmaceuticals shared new preclinical findings from its Enzymatic Antibody Glycan Ligation (EAGLE) platform and innovative bi-sialidase constructs during the American Association for Cancer Research (AACR) Annual Meeting 2024. The presented data underscored the potential of these strategies to boost anti-tumor immunity by modifying cell surface glycans....more
PR Newswire • January 4, 2024
Palleon Pharmaceuticals announced that the first patient has been dosed in its Phase 2 clinical study of E-602. This investigational immunotherapy is being evaluated in patients with non-small cell lung cancer (NSCLC) whose disease advanced after treatment with anti-PD-1/PD-L1 therapy. E-602 is an engineered human sialidase aimed at desialylating tumors and immune cells to counteract glycan-mediated immune suppression....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Palleon Pharmaceuticals, are just a search away.